Chromadex Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Niagen Bioscience Inc (NAGE)
Niagen Bioscience Inc stock price live, this page displays NASDAQ NAGE stock exchange data. View the NAGE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Niagen Bioscience Inc real time stock price chart below.
What Is the Niagen Bioscience Inc Stock Price Today?
The Niagen Bioscience Inc stock price today is 5.060.
What Is the Stock Symbol for Niagen Bioscience Inc?
The stock symbol for Niagen Bioscience Inc is "NAGE."
What Stock Exchange Does Niagen Bioscience Inc Trade On?
Niagen Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Niagen Bioscience Inc a Good Stock to Buy?
Determining whether Niagen Bioscience Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAGE quote. (ISIN: US1710774076)
What Is the Niagen Bioscience Inc Stock Price Today?
The Niagen Bioscience Inc stock price today is 5.060.
What Is the Stock Symbol for Niagen Bioscience Inc?
The stock symbol for Niagen Bioscience Inc is "NAGE."
What Stock Exchange Does Niagen Bioscience Inc Trade On?
Niagen Bioscience Inc is listed and trades on the NASDAQ stock exchange.
Is Niagen Bioscience Inc a Good Stock to Buy?
Determining whether Niagen Bioscience Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NAGE quote. (ISIN: US1710774076)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.842
5.230
52 wk Range
4.725
14.690
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.8425.230
52 wk Range
4.72514.690
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NAGE Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
13.600
Upside
+168.77%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
- Niagen Bioscience soars 38% on blowout Q4 results
- Investing.com
- Chromadex Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Niagen Bioscience soars 38% on blowout Q4 results
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Niagen Bioscience Inc Company Profile
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Niagen Bioscience Inc Earnings Call Summary for Q3/2025
- Niagen Bioscience (NAGE) exceeded Q3 2025 forecasts with EPS of $0.05 vs $0.02 expected and revenue of $34M vs $30.83M expected, despite stock dipping 3.73% after hours.
- Revenue grew 33% year-over-year to $34M with net income rising to $4.6M from $1.9M in Q3 2024, driven by a 109% increase in distribution business.
- Gross margin improved to 64.5% (up 100 basis points), with the company maintaining a strong cash position of $64.3M and no debt.
- Management revised full-year revenue growth guidance to 25-30%, announcing plans to launch a telehealth platform for at-home injections by mid-2026.
- Key challenges include regulatory hurdles like the FDA's NMN ruling, intense competition in NAD precursor products, and potential economic pressures on consumer spending.
Last Updated: 2025-11-04, 05:34 p/m
Read Full TranscriptCompare NAGE to Peers and Sector
Metrics to compare | NAGE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNAGEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.4x | −0.2x | 12.2x | |
PEG Ratio | 0.29 | 0.04 | 0.03 | |
Price/Book | 5.3x | 1.7x | 1.5x | |
Price / LTM Sales | 3.1x | 1.8x | 0.9x | |
Upside (Analyst Target) | 156.9% | 52.4% | 22.5% | |
Fair Value Upside | Unlock | 28.2% | 12.4% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 13.600
(+168.77% Upside)
Earnings
Latest Release
Mar 04, 2026
EPS / Forecast
0.05 / 0.02
Revenue / Forecast
33.80M / 31.70M
People Also Watch
FAQ
What Is the Niagen Bioscience (NAGE) Stock Price Today?
The Niagen Bioscience stock price today is 5.060 USD.
What Stock Exchange Does Niagen Bioscience Trade On?
Niagen Bioscience is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Niagen Bioscience?
The stock symbol for Niagen Bioscience is "NAGE."
What Is the Niagen Bioscience Market Cap?
As of today, Niagen Bioscience market cap is 406.050M USD.
What Is Niagen Bioscience's Earnings Per Share (TTM)?
The Niagen Bioscience EPS (TTM) is 0.220.
When Is the Next Niagen Bioscience Earnings Date?
Niagen Bioscience will release its next earnings report on May 13, 2026.
From a Technical Analysis Perspective, Is NAGE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Niagen Bioscience Stock Split?
Niagen Bioscience has split 1 times.
How Many Employees Does Niagen Bioscience Have?
Niagen Bioscience has 117 employees.
What is the current trading status of Niagen Bioscience (NAGE)?
As of Mar 08, 2026, Niagen Bioscience (NAGE) is trading at a price of 5.060 USD, with a previous close of 5.100 USD. The stock has fluctuated within a day range of 4.842 USD to 5.230 USD, while its 52-week range spans from 4.725 USD to 14.690 USD.
What Is Niagen Bioscience (NAGE) Price Target According to Analysts?
The average 12-month price target for Niagen Bioscience is 13.600 USD, with a high estimate of 18 USD and a low estimate of 12 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +168.77% Upside potential.
What Is the NAGE Premarket Price?
NAGE's last pre-market stock price is 5.011 USD. The pre-market share volume is 35,790.000, and the stock has decreased by -0.089, or -1.750%.
What Is the NAGE After Hours Price?
NAGE's last after hours stock price is 5.068 USD, the stock has decreased by 0.008, or 0.150%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.